EUCTR2019-003502-28-ES进行中（未招募）1 期
A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of AP-325 in Subjects with Peripheral Post-surgical Neuropathic Pain
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 94
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects must be at least 18 years and not older than 80 years
- •2. Subjects with a diagnosis of chronic post-surgical neuropathic pain after breast surgery (breast cancer interventions), chest surgery (i.e. thoracotomy, video assisted thoracoscopy and sternotomy) or groin hernia repair (i.e. femoral hernia repairs and inguinal hernia repairs)
- •3. The chronic post-surgical pain developed or increased in intensity after the surgical procedure and persisted beyond the healing process, i.e. at least 3 months after the initiating event, as defined according to the international association for the study of pain (IASP) classification of chronic pain for ICD-11 (Schug et al., 2019)
- •4. Subjects must have ‘probable’ or ‘definite’ neuropathic pain as assessed by the revised IASP special interest group on neuropathic pain (NeuPSIG) grading system (Finnerup et al., 2016)
- •5. Subjects must be willing to discontinue and washout prohibited substances including
- •pain medications (e.g. antidepressants, anticonvulsants/antiepileptics, selective serotonin and dual reuptake inhibitors, long-acting benzodiazepines, muscle relaxants, and topical analgesics), except the rescue medication, and
- •substances known to be inhibitors or inducers of CYP2C9 and inhibitors of CYP3A4
- •for specific washout periods of at least 5 times the drug half-life
- •6. Permitted concomitant medications must have been stable for at least 4 weeks prior to Day -14 and any non-pharmacological therapies (e.g. physiotherapy, acupuncture and transcutaneous electrical neural stimulation) must have been initiated at least 3 weeks prior to Screening
- •7. Female subjects must not be pregnant or breastfeeding and be
- •of non-childbearing potential or
- •if of childbearing potential, use a highly effective contraceptive method from start of the IMP intake until 30 days after the last IMP intake and have a negative pregnancy test at Screening (blood test)
- •8. Male subjects must agree, from start of the IMP intake until 3 months after the last IMP intake, to refrain from donating sperm and use a male condom when having sexual intercourse with a woman of childbearing potential at any time and advise her to use a highly effective contraceptive method
- •9. Subjects must understand the nature of the study procedures and provide written informed consent prior to any study-related procedures
- •10. Body weight =55 kg for men and =50 kg for women
- •11. Body mass index (BMI) <35 kg/m²
- •Randomization criteria
- •1. At least 5 daily pain assessments in the baseline week prior to randomization, with a mean score on the PI-NRS =4 and =9. Differences between the baseline daily pain scores on the PI-NRS must be =50%.
- •2. For female subjects of childbearing potential: negative pregnancy test in urine on Day 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 54
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1. Subjects with neuropathic pain not a result of a surgical procedure as defined in inclusion criterion 2
- •2. Subjects with any other coexisting pain that cannot be discriminated from post-surgical neuropathic pain, in the opinion of the subject or clinician
- •3. Subjects diagnosed with chronic post-surgical neuropathic pain with a disease duration exceeding 3 years
- •4. Inability to participate in the study, in the opinion of the investigator, because of, for example, severe brain damage, language barrier, dementia, or other clinically significant or unstable conditions
- •5. Subjects using adjuvant chemotherapy
- •6. Creatinine clearance <60 mL/min using the Cockcroft-Gault formula
- •7. White blood cell count <2500/mm³; neutrophil count <1500/mm³; platelet count <100 x 10³/mm³
- •8. A history of multiple drug allergies
- •9. History or presence of alcohol or drug abuse
- •10. Subjects using strong opioids (e.g. a Morphine Equivalent Dose [MED] >80 mg/day)
- •11. Positive test for drugs of abuse at Screening
- •12. Evidence of depression and/or a score of =11 on the HADS subscale
- •13. Psychiatric disease in the past 5 years
- •14. History of any liver disease within the last 6 months, or migraine, or kidney dysfunction or disease (e.g. estimated glomerular filtration rate [eGFR] =30 mL/min per 1.73 m²)
- •15. Clinically significant gastrointestinal conditions, likely interfering with the study medication, study procedures or the outcome of the study
- •16. Positive test for human immunodeficiency virus (HIV)
- •17. Positive test for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C antibody and/or HIV1/HIV2 antibody at Screening
- •18. Participation of subject in an interventional clinical study within 1 month or, if applicable, 5 half-lives of the IMP, whatever is longer, before Screening or during participation in this study
- •19. Previous enrolment in this clinical study
- •20. Known hypersensitivity to the active substance or any of the excipients of the IMP or the rescue medication
- •21. Subjects dependent (as an employee or relative) on the sponsor or investigator
- •22. Subjects committed to an institution by virtue of an order issued either by the judicial or the administrative authorities
- •23. Legal incapacity or limited legal capacity
研究者
相似试验
进行中（未招募）
1 期
Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabètes Post Worsening Heart Failure (SOLOIST-WHF Trial)Cardiovascular diseasesMedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-003510-16-FRSanofi-aventis Recherche & Développement6,667
进行中（未招募）
1 期
Efficacy and Safety of Sotagliflozin versus Placebo in Subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control while Taking Insulin Alone or with Other Oral Antidiabetic AgentsType 2 diabetes mellitusMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-001804-43-HUSanofi-aventis Recherche & Développement800
进行中（未招募）
1 期
Efficacy and Safety of Sotagliflozin versus Placebo in Subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control while Taking Insulin Alone or with Other Oral Antidiabetic AgentsType 2 diabetes mellitusMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-001804-43-BGSanofi-aventis Recherche & Développement571
进行中（未招募）
1 期
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn's DiseaseModerately to Severely Active Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code: 10011401Term: Crohn's disease Class: 100000004856CTIS2023-504737-41-00Janssen - Cilag International510
进行中（未招募）
1 期
Effect of Efpeglenatide on Cardiovascular OutcomesType 2 diabetes mellitusMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-002954-35-DKsanofi-aventis recherche & développement5,000